The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
The Lancet Neurology published positive Phase 2 data from the Vibrance-1 study of Alixorexton for narcolepsy type 1, demonstrating statistically significant improvements in wakefulness and sleepiness. The study of 92 adults showed that all tested doses (4 mg, 6 mg, 8 mg) achieved normative ranges on key sleep scales, with the treatment generally well tolerated and no serious adverse events reported.
Key figures
- Drug Name
- Alixorexton
- Phase Of Trial
- Phase 2
- Doses tested
- 4 mg, 6 mg, 8 mg
- Patient count
- 92
- Ess normative range score
- ≤10
- Mwt normative range minutes
- ≥20 minutes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.